FDA 522 Postmarket Surveillance Studies: Section 522 Order Compliance Guide

A 522 Order Is the Strongest Postmarket Tool FDA Can Aim at a Marketed Device

When the FDA concludes that a marketed device raises public-health questions the premarket data could not answer, it can order the manufacturer to run a Section 522 postmarket surveillance study. Codified at Section 522 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360l, and implemented by 21 CFR Part 822, this authority lets the agency compel systematic, scientifically valid data collection on a Class II or Class III device — at or after approval, and for up to (and beyond) three years.

A 522 order is distinct from the post-approval studies (PAS) the FDA imposes as a condition of PMA approval, and distinct from routine complaint handling and Medical Device Reporting (MDR). It is a standalone, FDA-directed surveillance obligation with firm statutory deadlines: a manufacturer has 30 days to submit a surveillance plan and 15 months to start the study. Every active 522 study is tracked in a public database that the FDA updates weekly.

This guide explains when the FDA orders a 522 study, how the statutory criteria work, the plan and timeline requirements, the study designs the agency accepts, how 522 differs from a PAS and from routine postmarket surveillance, the landmark 522 cases (surgical mesh and metal-on-metal hips), and what manufacturers should do to prepare for or respond to an order.

The Legal Basis: Section 522 and 21 CFR Part 822

Statutory authority

Section 522 of the FD&C Act gives the FDA the authority to require a manufacturer to conduct postmarket surveillance of certain Class II or Class III devices. The agency may issue the order at the time of clearance or approval, or at any time thereafter. Key legislative milestones:

The regulation

21 CFR Part 822 implements Section 522. It sets out who is covered (§ 822.4), what a surveillance plan must contain (§ 822.9 and § 822.10), design expectations, and reporting obligations. The accompanying guidance, "Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act" (finalized October 2022, which updates and replaces the May 2016 version), is the agency's current thinking on how to design and conduct these studies.

Postmarket surveillance under Section 522 is defined as the active, systematic, scientifically valid collection, analysis, and interpretation of data about a marketed device. It is not a substitute for the premarket data needed to support 510(k) clearance, PMA, HDE, or de novo authorization — it answers questions that emerge only after a device is on the market.

When Does FDA Order a 522 Study? The Four Triggers

FDA may order Section 522 surveillance for any Class II or Class III device that meets any one of the statutory criteria in 21 CFR 822.1 / Section 522(a)(1):

The pediatric trigger is notable because it applies to expected off-label pediatric use, not just labeled use. A device cleared for adults but foreseeably used in children can still trigger a 522 order.

How FDA decides to order

To identify where a 522 study is warranted, the FDA draws on:

• Adverse event reports (MAUDE / MDR data)
• A recall or corrective action
• Post-approval study data
• Review of the premarket submission
• Reports from other governmental authorities
• Review of the scientific literature

A 522 order specifies the device(s) subject to the order and the public-health question(s) the surveillance must answer. A single device can have more than one requirement imposed by the same order. The agency has emphasized that 522 is not the right tool for an acute safety emergency — recalls, removals, and field corrective actions are faster. 522 answers questions that take months or years to resolve.

The Statutory Timeline: 30 Days, 15 Months, 36 Months

Once a manufacturer receives a 522 order, three hard deadlines govern the work:

The 30-day plan

Within 30 days of receiving the order, the manufacturer must submit a surveillance plan that addresses the specific postmarket surveillance question(s) in the order. The plan content is specified in 21 CFR 822.9 and 822.10 and, per the 2022 guidance, is very similar to a rigorous clinical investigation plan. It must include:

• The surveillance question(s) and the study objectives derived from them
• The study design and rationale for why it can answer the question(s)
• The patient population, sample size justification, and enrollment plan
• The endpoints and how they will be measured
• Data collection methods, sources, and analysis plan
• The study timeline, milestones, and completion date
• Consideration of any patient-protection measures (IRB review, informed consent where applicable)

The 15-month commencement window

The manufacturer has 15 months from the date of the order to begin the surveillance. This window accounts for the time needed to finalize the plan with FDA, obtain IRB approval, set up sites or registries, and begin enrollment. Missing the commencement deadline puts the manufacturer out of compliance with the order.

The 36-month duration and reporting

The default surveillance period is 36 months from study start. Throughout the study, the manufacturer reports status and interim/final data summaries to the FDA, which posts them to the public 522 database. For devices with expected significant pediatric use, the agency may order surveillance longer than 36 months.

Accepted Study Designs

A 522 study does not have to be a randomized controlled trial. The 2022 guidance lists designs the agency will consider, and the manufacturer should pick the least burdensome approach that still rigorously answers the surveillance question:

FDA can also order surveillance of a predicate device where necessary — useful when the question concerns a whole device family or comparison to an earlier generation.

Oversight while the study runs

Because a 522 study that involves human subjects is FDA-regulated research, the standard clinical-trial oversight framework applies alongside the surveillance-specific rules:

• IRB review and approval (21 CFR Part 56) and informed consent (21 CFR Part 50) are required where the surveillance involves interaction with or intervention on human subjects
• Sponsor and investigator obligations under 21 CFR Part 812 (IDE) apply where the surveillance meets the definition of a clinical investigation
• FDA Bioresearch Monitoring (BIMO) inspections may be conducted at sponsor sites, clinical investigator sites, and IRBs to verify data quality, integrity, and human-subject protection — BIMO warning letters have been issued following 522/postmarket study inspections
• Study status, enrollment, and interim and final data summaries are reported to the FDA and published in the public 522 database

Manufacturers should treat a 522 study with the same data-integrity and human-subject-protection rigor as a premarket IDE study.

522 vs. Post-Approval Studies (PAS) vs. Routine PMS

These three postmarket mechanisms are often conflated. They have different legal bases, scopes, and triggers.

The practical upshot: a PAS is negotiated into your PMA approval and is a condition of keeping your device on the market. A 522 order can arrive later, sometimes years after approval, and can apply to a Class II 510(k) device — not just Class III PMAs.

Landmark 522 Cases

Two device categories made Section 522 famous and reshaped their regulatory classification.

Urogynecologic surgical mesh (2012)

In January 2012, the FDA ordered 522 postmarket surveillance studies for urogynecologic surgical mesh. By February 2013, the agency had issued:

• 95 orders to 34 manufacturers for surgical mesh used in transvaginal repair of pelvic organ prolapse (POP)
• 14 orders to 7 manufacturers for mini-sling devices for stress urinary incontinence (SUI)

The Boston Scientific and Coloplast 522 studies for transvaginal POP mesh were completed with 36-month follow-up data. The results showed mesh effectiveness and safety outcomes similar to native tissue repair at 36 months — but the FDA maintained that these devices nonetheless carried potential additional risks (mesh exposure and erosion) and did not have a favorable benefit-risk profile. The 522 findings directly supported FDA's reclassification of surgical mesh for transvaginal POP repair from Class II to Class III, requiring PMAs, and the effective removal of most such products from the market. In April 2024, the FDA released its review of the 522 studies on SUI mini-slings, finding them as effective as traditional mid-urethral slings at 36 months, and stated it would continue to require a 522 study for any mini-sling with a novel design.

Metal-on-metal hip implants (2011)

In 2011, the FDA raised safety concerns about metal-on-metal (MoM) hip implants, including potential bone and tissue damage from metal debris (metallosis) released by the articulating surfaces. These concerns drove a cluster of 522 orders and heightened postmarket scrutiny of MoM hip systems, contributing to the near-exit of MoM hip resurfacing from the U.S. market.

The 2011–2012 spike

FDA data show that 522 orders are relatively uncommon across most years — but there was a pronounced cluster around 2011–2012 driven by surgical mesh and metal-on-metal hips. The Government Accountability Office (GAO) reviewed the FDA's Section 522 practices in 2015, noting strengths and limitations of the program, including the time lag inherent in any multi-year surveillance tool.

The Public 522 Postmarket Surveillance Studies Database

Every active 522 study is tracked in the 522 Postmarket Surveillance Studies Database, a public, searchable database on FDA.gov. The database is sortable by manufacturer, device name, medical specialty, 522 order number, and date of order, and filterable by status (active, inactive, all).

The FDA updates the database every Sunday with new 522 requirements, new or revised study information (plan parameters, study status, interim or final data summaries), enrollment status, and reporting status. The public visibility is a deliberate accountability mechanism — slow enrollment or missed milestones are visible to anyone, including competitors and plaintiffs' counsel.

For definitions of terms used in the database, the FDA directs readers to the 2022 guidance, "Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act."

Preparing for a 522 Order

Most manufacturers will never receive a 522 order, but for higher-risk products — long-term implants, life-sustaining devices used outside facilities, devices with foreseeable pediatric use, or any device where failure could cause serious harm — readiness is prudent.

Common Misconceptions

Frequently Asked Questions

What is a Section 522 postmarket surveillance study?

It is an FDA-ordered postmarket study under Section 522 of the FD&C Act and 21 CFR Part 822. The FDA can require a manufacturer to conduct active, systematic, scientifically valid surveillance of a Class II or Class III device that meets one of four statutory criteria: failure reasonably likely to cause serious adverse health consequences, expected significant pediatric use, implantation for more than one year, or life-sustaining/supporting use outside a device user facility.

How quickly must a manufacturer respond to a 522 order?

The manufacturer must submit a postmarket surveillance plan to the FDA within 30 days of receiving the order, and must begin (commence) the surveillance within 15 months of the order date. The default surveillance duration is 36 months from study start, which may be extended for devices with expected significant pediatric use.

How is a 522 study different from a post-approval study (PAS)?

A PAS is imposed under Section 513(a)(3)(C) and 21 CFR 814.82 as a condition of PMA approval, typically at the time of approval. A 522 study is ordered under Section 522 and 21 CFR Part 822, can be issued at any time after clearance or approval, and applies to Class II as well as Class III devices. A single device can be subject to both a PAS and a 522 order.

Can FDA order a 522 study for a 510(k) device?

Yes. Section 522 applies to Class II and Class III devices. The 2012 surgical mesh 522 orders were issued for devices that were Class II at the time. Clearance pathway (510(k), de novo, PMA) does not determine 522 eligibility — device class and the statutory triggers do.

Are 522 study results public?

Yes. The FDA maintains the 522 Postmarket Surveillance Studies Database, which is updated every Sunday with new orders, study status, enrollment status, and interim and final data summaries. The database is publicly searchable by manufacturer, device, medical specialty, order number, and date.

Does the pediatric trigger require the device to be labeled for children?

No. The trigger is expected significant use in pediatric populations, whether or not the device is labeled for that use. A device cleared for adults but foreseeably used in children can meet the pediatric criterion.

What designs does FDA accept for a 522 study?

FDA accepts the least burdensome design that rigorously answers the surveillance question, including randomized controlled trials, observational/cohort studies, registries, prospective patient follow-up, literature reviews, nonclinical testing, and secondary data sources. The 2022 guidance describes these in detail.

Can FDA order surveillance of a predicate device?

Yes. Where necessary to answer the surveillance question, the FDA can order Section 522 surveillance of a predicate device, not just the device that triggered the concern.

Sources

• Section 522 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360l
• 21 CFR Part 822 — Postmarket Surveillance (eCFR)
• FDA, "Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act" (guidance for industry and FDA staff), October 2022 — updates and replaces the May 2016 version
• FDA, "522 Postmarket Surveillance Studies Program" and the 522 Postmarket Surveillance Studies Database (FDA.gov)
• FDA, "FDA's Activities: Urogynecologic Surgical Mesh" (522 orders issued January 2012; 95 POP orders to 34 manufacturers and 14 SUI mini-sling orders to 7 manufacturers by February 2013)
• FDA safety communications on metal-on-metal hip implants (2011)
• U.S. Government Accountability Office (GAO), review of FDA Section 522 postmarket surveillance practices (2015)
• FDA CERSI presentation, "Medical Device Clinical Evidence: IDEs and Beyond" (Section 522 statutory criteria and PAS comparison)